Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. Read more >>